Do peptides cause cancer? Separating hype from actual evidence

What's this video probably claiming?

The caption's wordplay, "Do peps cause the C word," is a pretty clear signal that @goodgutdoc is addressing one of the most persistent fears in the peptide therapy space: whether compounds like BPC-157, TB-500, GHK-Cu, or growth hormone secretagogues (GHSs) like CJC-1295 and ipamorelin promote cancer growth. The creator likely argues either that the cancer concern is overblown, that specific peptides are safer than critics claim, or takes a more nuanced position acknowledging real risks with certain compounds. Given the handle and category context, there's a decent chance BPC-157's gut-healing reputation is being defended, possibly alongside GHK-Cu's regenerative framing. What this video probably won't do is carefully separate "promotes tumor angiogenesis in vitro" from "causes cancer in healthy humans at clinical doses," because almost nobody on TikTok does that.

What does the science actually show?

The honest answer is: it depends enormously on the specific peptide, dose, and individual biology. BPC-157 has shown pro-angiogenic effects in some rodent models, which is a legitimate flag, since tumors need blood supply to grow. A 2018 study by Sikiric et al. in Current Pharmaceutical Design reviewed BPC-157's mechanisms and acknowledged angiogenic activity while arguing it operates through a nitric oxide pathway that differs from pathogenic angiogenesis. That distinction matters, but it hasn't been tested in oncology patients. GHSs like CJC-1295 and ipamorelin raise IGF-1 levels, and elevated IGF-1 has an established association with increased risk of colorectal, prostate, and breast cancers per a large meta-analysis by Rinaldi et al. (2010, Annals of Oncology). The word "association" is doing a lot of work there; correlation is not causation, and the IGF-1 levels produced by clinical GHS protocols are far below what's seen in acromegaly.

Where does the social media noise diverge from clinical reality?

The TikTok peptide community tends to flatten nuance in two directions simultaneously. On one side, you get catastrophizing: any peptide that touches IGF-1 or promotes cell growth is treated as a tumor accelerant. On the other, you get dismissal: "it's just a healing peptide, it can't cause cancer." Neither position reflects the literature. The realistic concern isn't that a healthy person using BPC-157 for a few months will develop cancer. It's that someone with an undiagnosed malignancy, or a genetic predisposition like Lynch syndrome, might be adding a pro-proliferative signal at exactly the wrong time. A 2021 review by Bitto et al. in Biomolecules noted that growth-promoting peptides warrant caution in oncology contexts specifically. Social media creators almost never mention contraindications for people with active or prior cancer, and that omission is a genuine patient safety gap.

What should you actually know?

There is no published human clinical trial demonstrating that BPC-157, TB-500, GHK-Cu, or any of the GHSs commonly discussed in peptide communities cause cancer in healthy adults. That's genuinely reassuring, but it's also a data gap, not a clean bill of health. These compounds are largely unregulated, compounded formulations vary in purity, and long-term human safety data simply does not exist. The FDA has not approved any of these peptides for therapeutic use, and several including BPC-157 have faced compounding restrictions. If you have a personal or family history of hormone-sensitive cancers, elevated baseline IGF-1, or active malignancy, the theoretical risks around GHSs and anabolic peptides are worth a real conversation with an oncologist, not a TikTok comment section. Anyone framing these compounds as universally safe is operating well outside what the current evidence actually supports.